Orly Moshe-Lilie

Orly Moshe-Lilie

Auto-generated profile, based on publicly available information

Orly Moshe-Lilie

Department of Neurology, Oregon Health & Science University, Portland, OR, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2011 in Inorganic Chemistry
Verified
Journal Article
Closed access
AJAmber M. Johnson
Amber M. Johnson
OMOrly Moshe
Orly Moshe
AGAna S. Gamboa
Ana S. Gamboa
BLBrian W. Langloss
Brian W. Langloss
JLJohn F. K. Limtiaco
John F. K. Limtiaco
RHRichard J. Hooley
Richard J. Hooley

28 July 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
OMOrly Moshe-Lilie
Orly Moshe-Lilie
AVAmy Visser
Amy Visser
NCNizar Chahin
Nizar Chahin
TRThomas Ragole
Thomas Ragole
DDDiana Dimitrova
Diana Dimitrova
CKChafic Karam
Chafic Karam
Objective To report our experience with adult patients with spinal muscular atrophy (SMA), some of whom were treated with nusinersen. Methods We reviewed charts of adult patients with SMA seen in our neuromuscular clinic between 2017 and 2019 and noted their demographics, clinical characteristics, treatment, and side effects. Results Twenty-two patients were included. Nine had type 2 and 13 type 3 SMA. Median age was 36 years (range 20–71). Most could not walk unassisted. Ten patients had significant respiratory impairment necessitating ventilation and 2 had tracheostomy. Seventeen had severe scoliosis. Ten patients were treated with nusinersen for 6–24 months (median 12 months), 3 of whom required bone laminectomy for intrathecal access. One developed bowel and bladder incontinence following the procedure. In the treated group, on average, % Medical Research Council change was 2.5% at 12 months and 3.9% at 24 months. Most untreated patients remained stable; 3 had slightly declined. Five treated patients reported subjective improvement. Treatment side effects included post lumbar puncture headache in 5 patients, 2 of whom needed blood patch, and 1 bacterial meningitis requiring inpatient treatment. Three patients stopped treatment after 12–24 months due to lack of improvement, recurrent pneumonia, or proteinuria. Conclusion Side effects of nusinersen can be serious. Whereas half of treated patients reported modest improvement in function, there were no significant objective changes, which may point largely to a placebo effect. Classification of evidence This study provides Class IV evidence that for some adult patients with SMA, nusinersen improves subjective function and causes serious adverse effects.

24 June 2020 in Amyloid
Verified
Journal Article
Closed access
OMOrly Moshe-Lilie
Orly Moshe-Lilie
DDDiana Dimitrova
Diana Dimitrova
SHStephen B. Heitner
Stephen B. Heitner
TBThomas H. Brannagan
Thomas H. Brannagan
SZSasha Zivkovic
Sasha Zivkovic
CKChafic Karam
Chafic Karam
Objective: Patients with hereditary transthyretin (TTR) amyloidosis (hATTR) often experience disease progression after orthotopic liver transplant (POLT) due in part to wild type ATTR amyloid deposition. The management strategy is not defined. We propose that TTR gene silencing with an antisense oligonucleotide or a small interfering ribonucleic acid may be a treatment for these patients. Methods: We reviewed the charts of hATTR patients POLT treated with a TTR gene silencing agent at 7 different Amyloid Clinics between 2018–2020. Results: Nine hATTR patients with POLT were treated with TTR gene silencing therapy (Inotersen). The median age was 61 years. The median time from OLT to initiation of TTR gene silencing therapy was 7.5 years. The median duration of therapy was 12 months. Neuropathy impairment score remained stable or improved in all patients. Five patients stopped treatment: 3 because of thrombocytopenia, 2 because of reversible liver rejection. Three patients who discontinued treatment subsequently experienced worsening of their neuropathy. Conclusion: TTR gene silencing therapy in hATTR patients with POLT could be a treatment option. Vigilant monitoring of renal, liver and bone marrow functions is necessary because of frequent complications. Further studies are needed to determine efficacy.

24 January 2012 in Organic Letters
Verified
Journal Article
Closed access
KDKatherine E. Djernes
Katherine E. Djernes
OMOrly Moshe
Orly Moshe
MMMagi Mettry
Magi Mettry
DRDonald D. Richards
Donald D. Richards
RHRichard J. Hooley
Richard J. Hooley

22 June 2012 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
YLYing Liu
Ying Liu
MYMichael Young
Michael Young
OMOrly Moshe
Orly Moshe
Quan ChengQuan Cheng
Quan Cheng
RHRichard J. Hooley
Richard J. Hooley

11 August 2020 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
OMOrly Moshe‐Lilie
Orly Moshe‐Lilie
LRLouis P. Riccelli
Louis P. Riccelli
CKChafic Karam
Chafic Karam